[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, Shimizu A, Hyodo M, Yasuda Y: Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP; 2010;11(1):36-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports.
  • CONTEXT: Although surgical resection is the only curative therapeutic option for recurrent or metachronous pancreatic carcinomas, most such cancers are beyond surgical curability.
  • We herein report on two rare cases of remnant pancreatectomy used to treat recurrent or metachronous pancreatic carcinomas.
  • CASE REPORTS: CASE#1 A 65-year-old male developed weight loss and diabetes mellitus 83 months after a pylorus-preserving pancreaticoduodenectomy followed by two years of adjuvant chemotherapy (5-fluorouracil plus leucovorin plus mitomycin C) for a pancreatic carcinoma in the head of the pancreas (stage IA).
  • An abdominal CT scan revealed a 3 cm tumor in the remnant pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant distal pancreatectomy was performed and a pancreatic carcinoma similar in profile to the primary lesion (stage IIB) was confirmed pathologically.
  • CASE#2 A 67-year-old male showed increased CA 19-9 levels 25 months after a distal pancreatectomy for a pancreatic carcinoma in the body of the pancreas (stage IA).
  • An abdominal CT scan revealed a cystic lesion in the cut end of the pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant proximal pancreatectomy with duodenectomy was performed and a metachronous pancreatic carcinoma (stage III) was confirmed pathologically.
  • CONCLUSION: Remnant pancreatectomy can be considered a treatment option for recurrent or metachronous pancreatic carcinomas.
  • FDG-PET can play a key role in detecting remnant pancreatic carcinomas.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Wang J, Jiang Y, Li J, Tian S, Ran W, Xiu D: Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res; 2009;28:88
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma.
  • BACKGROUND: To assess the feasibility and efficacy of using 125I seed implantation under intraoperative ultrasound guidance for unresectable pancreatic carcinoma.
  • METHODS: Fourteen patients with pancreatic carcinoma that underwent laparotomy and considered unresectable were included in this study.
  • Nine patients were pathologically diagnosed with Stage II disease, five patients with Stage III disease.
  • Fourteen patients were treated with 125I seed implantation guided by intraoperative ultrasound and received D90 of 125I seeds ranging from 60 to 140 Gy with a median of 120 Gy.
  • Five patients received an additional 35-50 Gy from external beam radiotherapy after seed implantation and six patients received 2-6 cycles of chemotherapy.
  • In this preliminary investigation, 125I seed implant provided excellent palliation of pain relief, local control and prolong the survival of patients with stage II and III disease to some extent.
  • [MeSH-major] Carcinoma / radiotherapy. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pancreas / pathology. Pancreas / radiography. Pancreas / ultrasonography. Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Dec 1;56(11):2563-8 [2864997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):759-63 [2984152.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Surg Gynecol Obstet. 1970 Jun;130(6):1049-53 [4192028.001]
  • [Cites] Cancer. 1983 Sep 1;52(5):808-13 [6191854.001]
  • [Cites] Ann Surg. 1984 Jan;199(1):1-5 [6419687.001]
  • [Cites] Pain Suppl. 1986;3:S1-226 [3461421.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):319-29 [3104244.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Ann Surg. 1988 Jun;207(6):648-54 [3389933.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2764-8 [7595736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1357-62 [16029793.001]
  • [Cites] Radiother Oncol. 2005 Jul;76(1):48-53 [15990186.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):399-403 [16680642.001]
  • [Cites] Ann Surg. 1984 Sep;200(3):289-96 [6205632.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1705-10 [7284971.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):709-14 [6244074.001]
  • [Cites] Am J Surg. 1978 Feb;135(2):185-91 [626289.001]
  • (PMID = 19545454.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radioisotopes
  • [Other-IDs] NLM/ PMC2715376
  •  go-up   go-down


3. Dickinson KJ, Gomez D, Lowe A, Gokhale JA, Ausobsky JR, Guillou PJ, Rahman SH: Carcinoma of the body of pancreas in evolution: an aggressive disease affecting younger patients? JOP; 2007;8(3):312-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the body of pancreas in evolution: an aggressive disease affecting younger patients?
  • CONTEXT: Pancreatic body carcinoma has a poor prognosis with advanced disease at presentation.
  • PARTICIPANTS: Thirty-one patients with pancreatic body carcinoma (median age at diagnosis 72 years; range 43-87 years).
  • There was a significantly (P=0.024) greater prevalence of more advanced tumours post MDT (stage IV: 15/23, 65.2%) than pre MDT (stage IV: 2/8, 25.0%).
  • Neither tumour markers nor liver biochemistry differentiated tumour stage.
  • Best supportive care was offered to 16 patients (51.6%) while 12 patients (38.7%) were suitable for chemotherapy: 2 out of 8 pre MDT (25.0%) and 10 out of 23 (43.5%) post MDT (P=0.433).
  • For stage III tumours, post MDT patients tended to be younger (median 59 years vs. 74.5 years, P=0.042).
  • Survival was not significantly increased after MDT introduction but chemotherapy offered significant survival benefit on multivariate analysis (P=0.042; hazard ratio: 0.39, 95% CI: 0.16-0.97).
  • CONCLUSION: The trend is towards increased prevalence of pancreatic body cancer and more advanced disease at presentation.
  • Chemotherapy was associated with a survival benefit, although the introduction of the MDT has not significantly altered disease management.
  • [MeSH-major] Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495360.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


Advertisement
4. Saif MW, Sviglin H, Carpenter M: Impact of ethnicity on outcome in pancreatic carcinoma. JOP; 2005 May;6(3):246-54
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of ethnicity on outcome in pancreatic carcinoma.
  • In pancreatic cancer, African Americans are thought to have a higher incidence and poorer prognosis than Whites.
  • PATIENTS: A total 645 pancreatic cancer patients were identified in the database, of which, 530 patients were eligible for this study and retained for the statistical analysis.
  • Overall, 132 patients out of 415 (31.8%) were seen in stage I, 61 (14.7%) in stage II, 105 (25.3%) in stage III, 117 (28.2%) in stage IV, while 115 patients (21.7%) had missing stage.
  • Overall, 125 (23.6%) received surgery alone, 54 (10.2%) surgery with chemotherapy, 5 (0.9%) surgery with external radiation therapy, 10 (1.9%) external radiation therapy alone, 68 (12.8%) chemotherapy alone, 58 (10.9%) chemo-external radiation therapy, and 210 (39.6%) no therapy.
  • There were more survivors in females (43/255, 16.9%) than in males (25/275, 9.1%; P=0.009), and females had significantly greater survival times as compared to males (P=0.022).
  • CONCLUSIONS: Pancreatic cancer is a disease of both ethnicities with a slight male predominance among Whites and female predominance among Blacks.
  • We did not find any significant difference in the treatment specific outcome and survival between Blacks and Whites.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / therapy. African Americans. European Continental Ancestry Group. Pancreatic Neoplasms / ethnology. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Characteristics. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15883475.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Udaka T, Konishi Y, Waki N, Hayama M, Kubo M, Sogabe O, Maeda H, Mizuta M, Shirakawa K: [Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer]. Gan To Kagaku Ryoho; 2008 Jun;35(6):937-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer].
  • The feasibility and anti-tumor activity of gemcitabine (GEM) as postoperative adjuvant chemotherapy were evaluated retrospectively.
  • Between September 1998 and June 2007, patients with resected invasive pancreatic cancer (stage III, IVa, IVb) were given adjuvant chemotherapy with GEM (GEM group, n=10) or did not receive chemotherapy (n=11).
  • There was a significant difference in overall survival between the GEM group and the no-chemotherapy group (p=0.037), but there was no significant difference in disease-free survival between the two groups.
  • Adjuvant chemotherapy with GEM was feasible and showed a benefit in patients with invasive pancreatic cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633220.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


6. Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene; 2000 Dec 27;19(56):6642-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
  • Experimental studies performed prior to 1990 led to the widely held belief that matrix metalloproteinases (MMPs) produced by cancer cells are of critical importance in tumor invasion and metastasis.
  • Based on this evidence, the pharmaceutical industry produced several well tolerated, orally active MMP inhibitors (MMPIs) which demonstrated efficacy in mouse cancer models.
  • Phase III clinical trials initiated in 1997-98 using marimastat, prinomastat (AG3340), and BAY 12-9566 alone or in combination with standard chemotherapy in patients with advanced cancers (lung, prostate, pancreas, brain, GI tract) have recently been reported; no clinical efficacy was demonstrated.
  • Bayer and Agouron have discontinued their ongoing Phase III drug trials of MMPIs in advanced cancer.
  • In retrospect, the failure of MMPIs to alter disease progression in metastatic cancer might have been anticipated since MMPs appear to be important in early aspects of cancer progression (local invasion and micrometastasis) and may no longer be required once metastases have been established.
  • Our understanding of MMP pathophysiology in cancer has expanded considerably in the past 10 years.
  • (1) most MMPs in tumors are made by stromal cells, not carcinoma cells;.
  • (2) cancer cells induce stromal cells to synthesize MMPs using extracellular matrix metalloproteinase inducer (EMMPRIN) and cytokine stimulatory mechanisms; and (3) MMPs promote cell migration and the release of growth factors sequestered in the extracellular matrix.
  • MMPs have a dual function in tumor angiogenesis: MMP-2 and MT1-MMP are required in breaking down basement membrane barriers in the early stage of angiogenesis, while other MMPs are involved in the generation of an angiogenic inhibitor, angiostatin.
  • In spite of considerable recent progress in identifying multiple roles of MMPs in disease, our understanding of MMP function in cancer is far from complete (see Table 1).
  • (1) patients with early stage cancer;.
  • (2) the use of MMPIs along with chemotherapy;.
  • (3) the measurement of MMPs in tumor tissue and blood as a means of identifying patients who are more likely to respond to MMPI therapy; and (4) identification of biomarkers that reflect activation or inhibition of MMPs in vivo.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Matrix Metalloproteinase Inhibitors. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Design. Drug Evaluation, Preclinical. Humans. Matrix Metalloproteinases / chemistry. Matrix Metalloproteinases / physiology. Mice. Models, Biological. Neoplasm Metastasis. Neovascularization, Pathologic. Stromal Cells / enzymology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426650.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 75
  •  go-up   go-down


7. Saif MW: New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. JOP; 2008;9(4):391-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
  • Pancreatic cancer remains a major therapeutic challenge in 2008.
  • The annual incidence rate of pancreatic cancer is almost identical to the mortality rate; approximately 37,000 new cases are diagnosed each year in the United States, and approximately 33,000 patients die from this disease.
  • Poor prognosis has been attributed to an inability to diagnose pancreatic cancer at an early stage.
  • Majority of patients have advanced pancreatic cancer at the time of diagnosis.
  • Advanced disease is associated with a dismal outcome, with a median survival of 3-6 months.
  • CONKO-001 study: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer.
  • E4201 study: a randomized phase III study of gemcitabine in combination with radiation therapy vs. gemcitabine alone in patients with localized, unresectable pancreatic cancer.
  • AViTA study: a randomized, double-blind, placebo-controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer.
  • CONKO-003 study: final results of a randomized trial in patients with gemcitabine-refractory pancreatic cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic / statistics & numerical data. Combined Modality Therapy / adverse effects. Combined Modality Therapy / trends. Humans. Multicenter Studies as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 3.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648128.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


8. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer.
  • AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with (125)iodine seed implantation for unresectable pancreatic cancer.
  • METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study.
  • The tumor, 4-12 cm in diameter, located in pancreatic head of 23 patients and in pancreatic body and tail of 9 patients, was found to be unresectable during operation.
  • Diagnosis of pancreatic cancer was made through intraoperative biopsy.
  • In brief, a RFA needle was placed, which was confirmed by intraoperative ultrasound to decrease the potential injury of surrounding vital structures, a (125)iodine seed was implanted near the blood vessels and around the tumor border followed by bypass palliative procedure (cholangio-jejunostomy and/or gastrojejunostomy) in 29 patients.
  • The pain score on day 7 after operation, 1 and 3 mo after combined therapy was decreased from 5.86 ± 1.92 before operation to 2.65 ± 1.04, 1.65 ± 0.88 and 2.03 ± 1.16, respectively, after operation (P < 0.05).
  • The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • The median survival time of patients who received and did not receive chemotherapy after operation was 20 mo and 16 mo, respectively (P = 0.0176).
  • All the patients recovered well after conservative support treatment.
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.
  • [MeSH-major] Adenocarcinoma / therapy. Catheter Ablation / methods. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / therapy. Radiotherapy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


9. Kochi M, Fujii M, Kanamori N, Kaiga T, Takahashi T, Kobayashi M, Takayama T: Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer. J Cancer Res Clin Oncol; 2006 Dec;132(12):781-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
  • PURPOSE: This retrospective study evaluated the effects of neoadjuvant chemotherapy in advanced gastric cancer.
  • METHODS: Between 2002 and 2005, we treated 14 patients with advanced gastric cancer (involvement of more than five nodes or tumor invasion into pancreas) and 25 patients with Stage III gastric cancer.
  • The group of 14 patients with advanced gastric cancer received combination chemotherapy with S-1 and cis-diamminedichloroplatinum (CDDP) as a neoadjuvant chemotherapy (NAC).
  • The 25 patients with Stage III gastric cancer was carried surgery alone (SA).
  • RESULTS: All patients of NAC group completed the planned regimens of chemotherapy and surgery.
  • CONCLUSION: Neoadjuvant chemotherapy with TS-1 + CDDP improves the survival in patients with advanced gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy / adverse effects. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2004 May 17;90(10):1888-92 [15138467.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1727-32 [15150592.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Oncology. 2004;67(1):48-53 [15459495.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1155-9 [12209246.001]
  • [Cites] J Clin Oncol. 1996 Jun;14 (6):1818-28 [8656250.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1103-9 [16106493.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6957-65 [16145066.001]
  • [Cites] Oncology. 2004;66(6):445-9 [15452373.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1269-75 [7999411.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):212-23; discussion 223 [11992807.001]
  • (PMID = 16804723.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Mambrini A, Bassi C, Pacetti P, Torri T, Iacono C, Ballardini M, Orlandi M, Guadagni S, Fiorentini G, Cantore M: Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. Pancreas; 2008 Jan;36(1):56-60
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
  • OBJECTIVES: The aim of this study is to identify the prognostic factors of a large group of patients with pancreatic cancer who underwent the same regimen of intra-arterial chemotherapy.
  • RESULTS: Data of 211 patients with advanced pancreatic cancer who underwent FLEC regimen were analyzed.
  • In both univariate and multivariate analyses, pain reduction after treatment (< or =30% of baseline level vs >30%; overall survival, 7.6 vs 11.5 months), stage of disease (III vs IV; overall survival, 10.5 vs 6.6 months), and number of administered cycles (< or =3 vs >3; overall survival, 5.9 vs 12.3 months) were significant and independent predictors of survival.
  • CONCLUSIONS: Pain reduction, stage of disease, and number of administered cycles are independent prognostic factors of overall survival in a multivariate analysis of patients with advanced pancreatic cancer receiving FLEC regimen intra-arterially.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Pain. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192882.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEC protocol
  •  go-up   go-down


11. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Between 1987 and 2004, 111 patients underwent pancreatic resection against invasive ductal carcinoma of the pancreas in Wakayama Medical University Hospital.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Ema T, Arai K, Maeda Y, Iwasaki Y, Katayanagi S, Takahashi K, Yamaguchi T, Takahashi T: [A case of curatively resected gastric cancer through an effective response to chemotherapy]. Gan To Kagaku Ryoho; 2004 Jun;31(6):925-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of curatively resected gastric cancer through an effective response to chemotherapy].
  • The patient is a 66-year-old male who underwent gastrojejunostomy at another hospital with the diagnosis of type 3 unresectable gastric cancer.
  • He was admitted to our hospital for adjuvant chemotherapy.
  • A CT scan revealed both peritoneal dissemination and a large tumor directly invading the pancreas and liver.
  • After 7 courses of combined chemotherapy with 5-FU, Leucovorin, cis-platinum and methotrexate, an effective response, tumor reduction and the disappearance of peritoneal dissemination, was verified by CT scan.
  • Pancreatoduodenectomy with transverse colectomy was carried out and the pathological diagnosis was also curative (pT3, pN1, pP0, HO: stage III A).
  • We think this case shows the possibility of NAC for patients with far advanced gastric cancer with peritoneal dissemination to improve their prognosis or QOL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Jejunostomy. Leucovorin / administration & dosage. Liver Neoplasms / pathology. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Neoadjuvant Therapy. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / pathology. Quality of Life

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222114.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


13. Fahrig R, Quietzsch D, Heinrich JC, Heinemann V, Boeck S, Schmid RM, Praha C, Liebert A, Sonntag D, Krupitza G, Hänel M: RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients. Anticancer Drugs; 2006 Oct;17(9):1045-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients.
  • RP101 [(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)], which supports apoptosis and prevents the acquisition of chemoresistance, was tested in cultured human pancreatic tumor cells.
  • This was concomitant with an enhanced expression of lymphotoxins alpha and beta, natural killer cell transcript 4, tumor necrosis factor LIGHT/TNFSF-14, and intercellular adhesion molecule-1 in pancreas carcinoma cells.
  • These results encouraged us to investigate the effect of RP101 in pancreas cancer patients.
  • Here, we present data from two RP101 combination therapy schemes.
  • In a first pilot study, 13 patients in stage III and VI of the disease were treated with gemcitabine +cisplatin+RP101.
  • RP101 co-treatment enhanced remissions, survival and time to progression.
  • Median survival was 447 days, time to progression 280 days and the response rate 33%.
  • The data indicate that acquisition of chemoresistance was prevented and the antitumor efficacy of standard chemotherapy was improved.
  • To our knowledge, RP101 co-treatment is more efficient than any other regimen published.
  • [MeSH-major] Bromodeoxyuridine / analogs & derivatives. Pancreatic Neoplasms / drug therapy


14. Katsumata K, Tomioka H, Sumi T, Yamasaki T, Takagi M, Kato F, Suzuki Y, Aoki T, Koyanagi Y: Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. Int J Clin Oncol; 2003 Apr;8(2):110-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
  • A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres.
  • The patient was a 52-year-old woman who had undergone surgery for cancer of the head of the pancreas in October 1996.
  • She had stage III disease and was followed up as an outpatient on oral therapy with a combined uracil and tegafur preparation.
  • In October 2000, abdominal computed tomography (CT) scans detected multiple liver metastases.
  • After three more courses of this therapy, the patient developed bile duct necrosis and died of disseminated intravascular coagulation.
  • As her metastases were controlled for about 7 months, hepatic arterial infusion of mitomycin C and degradable starch microspheres appears to be useful for treating liver metastasis of pancreatic cancer, but careful attention should be paid to the risk of severe complications such as bile duct necrosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Duct Diseases / chemically induced. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / secondary. Doxorubicin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Starch / adverse effects
  • [MeSH-minor] Chemoembolization, Therapeutic / adverse effects. Chemoembolization, Therapeutic / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Necrosis. Neoplasm Staging. Pancreaticoduodenectomy / methods. Risk Assessment. Tomography, X-Ray Computed


15. Tanigawa T, Hasuike Y, Yamada M, Fujiwara S, Murata H: [Case report of infected pseudo-aneurysm after intra-arterial chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2085-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of infected pseudo-aneurysm after intra-arterial chemotherapy].
  • Computed tomography (CT) showed a mass in the head of the pancreas and a dilated bile duct.
  • After performing preoperative biliary drainage, we conducted pancreatico-duodenectomy (PD-II: T3, N1, stage III).
  • As adjuvant chemotherapy, the patient received a hepatic arterial infusion with 5-FU to prevent liver metastasis.
  • A catheter was placed in the right femoral artery and intra-arterial chemotherapy was carried out for one week.
  • After the completion of chemotherapy, swelling and redness of the right inguinal region was observed.
  • Despite intravenous antibiotic therapy for 2 days, bleeding and pus discharge at the catheter root were observed.
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Male. Middle Aged. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037331.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg; 2000 Jan;135(1):81-7; discussion 88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
  • HYPOTHESIS: Neoadjuvant therapy has the potential to induce regression of high-risk, locally advanced cancers and render them resectable.
  • Preoperative chemoradiotherapy is proposed as a testable treatment concept for locally advanced pancreatic cancer.
  • DESIGN: Fourteen patients (8 men, 6 women) with locally advanced pancreatic cancer were surgically explored to exclude distant spread of disease, to perform bypass of biliary and/or gastric obstruction, and to provide a jejunostomy feeding tube for long-term nutritional support.
  • A course of chemotherapy with fluorouracil and cisplatin plus radiotherapy was then initiated.
  • Reexploration and resection were planned subsequent to neoadjuvant therapy.
  • INTERVENTIONS: Surgically staged patients with locally advanced pancreatic cancer were treated by preoperative chemotherapy with bolus fluorouracil, 400 mg/m2, on days 1 through 3 and 28 through 30 accompanied by a 3-day infusion of cisplatin, 25 mg m2, on days 1 through 3 and 28 through 30 and concurrent radiotherapy, 45 Gy.
  • RESULTS: Of 14 patients who enrolled in the protocol and were initially surgically explored, 3 refused the second operation and 11 were reexplored; 2 showed progressive disease and were unresectable and 9 (81%) had definitive resection.
  • Surgical pathologic stages of the resected patients were: Ib (2 patients), II (2 patients), and III (5 patients).
  • Pancreatic resection included standard Whipple resection in 1 patient, resection of body and neck in 1 patient, and extended resection in 6 patients (portal vein resection in 6, arterial resection in 4).
  • One patient who was considered too frail for resection had core biopsies of the pancreatic head, node dissection, and an interstitial implant of the tumorous head.
  • Pathologic response: 2 patients had apparent complete pathologic response; 1 patient had no residual cancer in the pancreatectomy specimen, the other patient who had an iridium 192 interstitial implant had normal core biopsies of the pancreatic head.
  • Five patients had minimal residual cancer in the resected pancreas or microscopic foci only with extensive fibrosis, and 2 patients had fully viable residual cancer.
  • In the definitive surgery group the median survival was 19 months after beginning chemoradiotherapy and 16 months after definitive surgery.
  • The absolute 5-year survival was 11% of 9 patients, 1 is surviving 96 months (with no evidence of disease) after chemoradiotherapy and extended pancreatic resection including resection of the superior mesenteric artery and the portal vein for stage III cancer.
  • CONCLUSION: A pilot study of preoperative chemoradiotherapy with infusional cisplatin and radiation induced a high rate of clinical pathologic response in patients with locally advanced pancreatic cancer and merits further study in these high-risk patients.
  • [MeSH-major] Neoadjuvant Therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Radiotherapy Dosage. Reoperation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10636353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Itoh Y, Fuwa N, Shinoda M: A case of esophageal carcinoma surgically treated after discontinuance of the simultaneous application of radiotherapy and chemotherapy with low doses of CDDP and 5-FU. Radiat Med; 2000 Jan-Feb;18(1):55-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of esophageal carcinoma surgically treated after discontinuance of the simultaneous application of radiotherapy and chemotherapy with low doses of CDDP and 5-FU.
  • The patient, a 69-year-old man with esophageal cancer, had a type 2 tumor in the Mt region, accompanied with an ulcer measuring 12 cm in the major axis.
  • The clinical stage of the lesion was T3N1M0 (stage III), and simultaneous therapy combining radiotherapy (2 Gy/day) with chemotherapy employing CDDP (6 mg/day) and 5-FU (300 mg/day) was started on October 21, 1996.
  • During treatment, tumor invasion into the gastric walls from lymph node metastasis was observed on endoscopy, and radiotherapy was discontinued at a total dose of 40 Gy to avoid the possibility of bleeding.
  • Although tumor invasion from lymph node metastasis in the lesser curvature of the stomach was observed in the pancreas, no remaining cancer cells were noted in the primary nest and metastasized lymph node, suggesting the usefulness of the simultaneous combined therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Esophagectomy. Esophagoscopy. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Pancreatic Neoplasms / secondary. Radiotherapy Dosage. Stomach Neoplasms / secondary. Stomach Ulcer / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10852656.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • The GIP-1 randomized phase III trial (clinicaltrials.gov ID NCT00813696 ) was performed to compare the combination of cisplatin (P) and G vs. G alone as 1st-line treatment.
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).
  • In Arm B, P 25 mg/m2 weekly (with the exception of day 22) was added to G, same dose used in Arm A (Colucci et al, Cancer 2002; 94:902-10).
  • Median age was 63 yrs (range 35-75), 59% were males, 84% stage IV, 83% KPS≥80.
  • CONCLUSIONS: Weekly combination of P and G, compared to single-agent G as 1st-line treatment of APC, failed to demonstrate any improvement in OS, PFS, ORR and clinical benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Viúdez A, Rodríguez J, De La Cámara J, Salgado E, Chopitea A, Gil-Bazo I, García-Foncillas J, Valero J, Espinós J, Martin-Algarra S: Triplet therapy with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4252

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet therapy with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
  • : 4252 Background: To determine the activity and tolerance of gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
  • METHODS: Thirty-two patients with confirmed diagnosis of stage IV pancreatic carcinoma, with a median age of 60 years and ECOG performance of 0 to 2 (59.4% ECOG 1), received gemcitabine 800 mg/m<sup>2</sup> intravenously (iv) days 1 and 14, cisplatin iv 75 mg/m<sup>2</sup> day 1, leucovorin 500 mg/<sup>2</sup> iv days 1 and 14 and 5-fluorouracil (FU) 2600 mg/m<sup>2</sup> iv days 1 and 14.
  • 87 % of patients were chemotherapy naive.
  • 13 % of patients had received prior chemotherapy, including cisplatin (6.3%), gemcitabine (6.3%), FU (6.3%) or docetaxel (3.1%).
  • Grade III/IV leucopenia, neutropenia or anemia was found in 21.8 %, 37.5 % and 19.25 %, respectively.
  • Main non-haematological grade III/IV toxicities included asthenia (18.8 %) anorexia (12.5 %) and nausea (9.4 %).
  • 10 patients (31.3 %) progressed while on-therapy.
  • With a median follow-up of 25 months (range 5.6 to 52.83), the median time to progression was 4.67 months (95% CI: 3.61 to 5.73), and the median overall survival was 10.23 months (95% CI: 4.30 to 14).
  • CONCLUSIONS: The combination of gemcitabine, FU, leucovorin and cisplatin, has moderate activity in metastatic carcinoma of the pancreas at an expense of an acceptable toxicity profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ueno M, Ohkawa S, Sakamoto Y, Miyakawa K, Miyagi Y: The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer.
  • : e15629 Background: The standard chemotherapy of advanced pancreatic cancer is still gemcitabine and recently gemcitabine + EGFR tyrosine kinase inhibitor (TKI)is noted to be positive on Phase III study.
  • In lung cancer, EGFR mutations (the deletion of exon 19, the point mutation of exon 18, 21) have been reported to be correlated with the effect of EGFR TKI.
  • On the other hand, such EGFR mutations were not reported to be recognized by the direct sequencing method in pancreatic cancer.
  • This time we examined EGFR expressions and EGFR mutations in advanced pancreatic cancer.
  • METHODS: We examined EGFR expressions immunohistochemically and EGFR mutations by Loop-Hybrid Mobility Shift Assay (LH-MSA) which is more sensitive than the direct sequencing method in the tissue obtained from percutaneous biopsies in advanced pancreatic cancer patients.
  • RESULTS: The subjects were 31 inoperable pancreatic cancer patients.
  • Patients received chemotherapy (gemcitabine: 10, S-1: 8, gemcitabine+S-1: 12, no treatment: 1).The UICC stages were as follows:stage II; 2, stage III; 6, stage IV; 23.
  • The tissues were obtaind from liver; 12, pancreas; 19.
  • Although LH-MSA were performed successfully in all patients, the same EGFR mutations as lung cancer were not detected.
  • CONCLUSIONS: EGFR expressions were not correlated with survivals and the same EGFR mutations as lung cancer were not detected in inoperable advanced pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any.
  • METHODS: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV.
  • These participants did not receive any other conventional or investigational cancer treatments.
  • The participants report no side effects from the drug psorinum.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.
  • Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Chiappori A, Simon GR, Kvols L, Tetteh L, Mahany JJ, Lush R, Sullivan DM: Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity.
  • RESULTS: A total of 10 patients were enrolled from April 2002 to October 2002.Patient characteristics were M/F 5/5; age range 24 to 65, ECOG PS 0/1=1/9; number of prior treatments 0/1/2/3= 4/2/3/1; median number of cycles given=3 (range 1 - 8).
  • Tumor types enrolled were NSCLC = 3, Carcinoid = 3, and 1 each of Head and Neck Cancer, Mesothelioma, Sarcoma and Islet Cell Cancer of the pancreas.
  • Two deaths occurred in previously treated advanced stage NSCLC patients.
  • The subsequent cohort of 6 patients tolerated chemotherapy well with no first-cycle or second-cycle grade III or IV neutropenia or thrombocytopenia.
  • A phase II trial of extensive stage SCLC is planned with this regimen with correlative intra-tumoral top I and II estimations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Schuetz T, Marshall J, Kaufman HL, Safran H, Panicali D: Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):2564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer.
  • : 2564 Background: Recombinant pox viruses have been developed as therapeutic anti-tumor vaccines.
  • Previous studies have demonstrated a correlation between the generation of T-cell immunity by these vaccines and overall survival (OS).
  • Twenty-two patients with advanced pancreatic cancer (Stage III or IV) were enrolled (20 with metastatic disease; all had received prior therapy).
  • CONCLUSIONS: All of the patients in the first study had metastatic disease at baseline and all had failed first-line chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015248.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Prost P, Ychou M, Azria D: [Gemcitabine and pancreatic cancer]. Bull Cancer; 2002 Aug;89 Spec No:S91-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine and pancreatic cancer].
  • [Transliterated title] Gemcitabine et cancer du pancréas.
  • The late diagnosis of pancreatic cancer, at a locally advanced and metastatic stage explains in part its poor prognosis.
  • These trials led to the realization of a randomized phase III study including 126 patients.
  • The study compared the use of gemcitabine, in monotherapy, with fluoro-uracil (5FU), the standard form of treatment.
  • Used in monotherapy, gemcitabine thus obtained authorization in 1996 to be released in the United States and in 1998 in Europe, to be used in the case of locally advanced or metastatic adenocarcinoma of the pancreas as first line chemotherapy.
  • It is currently considered as the standard chemotherapy in this situation.
  • Trials have been carried out to optimize the scheme for the administration of gemcitabine by lengthening its perfusion time.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Analgesia. Clinical Trials as Topic. Drug Administration Schedule. Europe. Fluorouracil / administration & dosage. Hematologic Diseases / chemically induced. Humans. Palliative Care. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12449037.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 20
  •  go-up   go-down


25. Arkosy P, Sasi SL, Enyedi A, Szántó J, András C, Sápy P: [Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy]. Magy Seb; 2005 Feb;58(1):29-33
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy].
  • [Transliterated title] Inoperábilis pancreas-carcinoma neo- adjuváns kemoterápiát követo kuratív sebészetének korai tapasztalatai.
  • In the treatment of pancreatic cancer only curative resection increases the life expectancy.
  • At the time of diagnosis most patients are in stage (TMN of pancreatic cancer UICC 1997) III or IV, thus curative resection cannot be performed.
  • Neo-adjuvant therapy shrinks the tumour in 60-70%, giving new hope for the patients.
  • In this paper authors present two cases of pancreatic cancer resections.
  • Palliative operations were performed in patients with inoperable pancreatic cancer.
  • Later neo-adjuvant chemotherapy was performed--in these cases it meant chemotherapy--and after that a second, this time curative procedure was performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Pancreatectomy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018598.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


26. Oman M, Lundqvist S, Gustavsson B, Hafström LO, Naredi P: Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. Cancer Chemother Pharmacol; 2005 Dec;56(6):603-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
  • BACKGROUND: Systemic palliative treatment with chemotherapy against advanced pancreas cancer has low effectiveness despite considerable toxicity.
  • AIM: To investigate the safety, toxicity and tumour response of intraperitoneal 5-Fluorouracil (5-FU) with intravenous Leucovorin and to monitor 5-FU pharmacokinetics in plasma during intraperitoneal instillation with and without vasopressin in patients with non-resectable pancreas cancer.
  • PATIENTS/METHODS: Between 1994 and 2003, 68 patients with non-resectable pancreas cancer TNM stage III and IV, were enrolled to receive intraperitoneal5-FU instillation 750-1500 mg/m2 and intravenous Leucovorin 100 mg/m2 for two days every third week.
  • RESULTS: The treatment was well tolerated with minor toxicity.
  • Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).
  • There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).
  • 5-FU AUC in plasma was not significantly affected by vasopressin either day of treatment.
  • CONCLUSION: Intraperitoneal 5-FU is a safe treatment with low toxicity to patients with non-resectable pancreas cancer.
  • Tumour response was 4.4% and median survival time 8.0 months.
  • Addition of vasopressin did not significantly decrease plasma 5-FU AUC but reduced Cmax on day 2 of treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Hemostatics / administration & dosage. Pancreatic Neoplasms / drug therapy. Vasopressins / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047145.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Hemostatics; 11000-17-2 / Vasopressins; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Boadas J, Balart J, Capellà G, Lluís F, Farré A: Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy. Rev Esp Enferm Dig; 2000 May;92(5):316-25
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy.
  • OBJECTIVE: The ominous prognosis of pancreatic carcinoma (PC) has led to a nihilistic attitude among physicians, and to the need to develop better tools for diagnosis, staging and treatment.
  • The aim of this study was to analyze a series of patients with PC in order to determine stage-related survival, and to try to improve diagnostic and therapeutic strategies.
  • TNM stage and survival were calculated.
  • We also analyzed age, sex, time elapsed until diagnosis, diagnostic tests, size and location, cytologic pathology confirmation, number of patients undergoing surgery, and procedures used.
  • Time elapsed until diagnosis: 3 +/- 15.7 months.
  • TNM staging: stage I 13%; stage II 25%; stage III 20%; stage IV 42%.
  • Stage-related survival: stage I 14 months; stage II 6 months; stage III 4 months; stage IV 1 month.
  • In 55% of the patients surgery revealed a higher stage of disease than had been diagnosed preoperatively.
  • CONCLUSIONS: Diagnosis was made at a late stage in many patients.
  • Early diagnosis, preoperative staging and postoperative management should be improved in these patients, and surgery should be associated with complementary chemotherapy and/or radiotherapy.
  • [MeSH-major] Pancreatic Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10927931.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


28. Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G: Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol; 2010 Oct;33(5):461-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
  • BACKGROUND: Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support.
  • PATIENTS AND METHODS: A retrospective survey was carried out including 40 patients with stage III or IV gemcitabine-refractory pancreatic carcinoma.
  • Response evaluation criteria in solid tumors and National Cancer Institute common toxicity criteria were employed respectively for response and toxicity assessment.
  • The median time to progression was 3.7 (range, 1-6.5 months), and median overall survival was 6 months (range, 2-8.2 months).
  • A stabilization of performance status and a subjective improvement of cancer-related symptoms were recorded in 21 patients (52.5%).
  • No correlation has been found between length of time to progression during first-line chemotherapy and length of that reported in the second-line setting or objective response.
  • CONCLUSIONS: Data presented in this article demonstrate that the second-line FOLFIRI regimen are able to induce an objective response in a relatively small fraction of patients with gemcitabine-refractory adenocarcinoma of the pancreas.
  • The use of second-line chemotherapy should be carefully proposed to patients with good performance status or those who had a good response to first-line therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Drug-Related Side Effects and Adverse Reactions. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142727.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


29. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol; 2009 Nov 20;27(33):5513-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
  • PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer.
  • PATIENTS AND METHODS: Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status <or= 2 were recruited.
  • This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).
  • CONCLUSION: On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Confidence Intervals. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Proportional Hazards Models. Quality of Life. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Time Factors. Treatment Outcome. United Kingdom

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Nov 20;27(33):5487-91 [19858387.001]
  • (PMID = 19858379.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G9900432
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Niebler K, Garbrecht M, Heinemann V: Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie; 2003 Oct;26(5):462-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
  • BACKGROUND: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
  • PATIENTS AND METHODS: Enrolled in the study were 87 patients (female/male = 26/61; stage III/IV disease = 24/63).
  • Serum samples were collected at the onset of chemotherapy and before the start of a new treatment cycle (day 28).
  • 43 (55.8%) patients were CA 19-9 responders, defined by a > or = 50% decrease in CA 19-9 serum levels within 2 months after treatment initiation.
  • CONCLUSION: CA 19-9 kinetics in serum serve as an early and reliable indicator of response and help to predict survival in patients with advanced pancreatic cancer receiving effective treatment with gemcitabine and cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Prognosis. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • (PMID = 14605463.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Wehrschütz M, Stöger H, Ploner F, Hofmann G, Wolf G, Höfler G, Krippl P, Samonigg H: Seminoma metastases mimicking primary pancreatic cancer. Onkologie; 2002 Aug;25(4):371-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seminoma metastases mimicking primary pancreatic cancer.
  • BACKGROUND: A case of seminoma clinical stage III, arising from the right testis and mimicking a primary pancreatic malignancy is reported.
  • Abdominal CT scan showed a tumor in the head of the pancreas and multiple pathologically enlarged peripancreatic lymph nodes.
  • A laparoscopic biopsy out of a suspicious lesion of the head of the pancreas and a surrounding lymph node was done.
  • 4 cycles of chemotherapy including cisplatinum, etoposide and bleomycin led into complete response that is still ongoing.
  • CONCLUSION: This case shows a seminoma with metastases at retroperitoneal site, mimicking a primary pancreatic neoplasm.
  • [MeSH-major] Pancreatic Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Pancreas / pathology. Tomography, X-Ray Computed


32. Radford IR: Gd-Tex Pharmacyclics Inc. Curr Opin Investig Drugs; 2000 Dec;1(4):524-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacyclics is developing Gd-Tex (gadolinium texaphyrin) as a radiosensitizer for the potential treatment of various cancers including brain metastases and primary brain tumors, pancreatic tumors, lung tumors and pediatric cancers [196711], [348919].
  • The compound entered phase III pivotal trials for brain metastases in September 1998 [323929].
  • Phase I clinical trials for the treatment of primary brain tumors and pancreatic cancer have been initiated while several trials in other cancer types are in the planning stages [367716].
  • In September 1998, Pharmacyclics announced the initiation of a pivotal phase III trial for the treatment of patients with brain metastases.
  • In September 2000, Pharmacyclics and the National Cancer Institute (NCI) initiated two phase I trials of Gd-Tex.
  • The first was to determine the safety of two different dosing regimens of the drug during preoperative radiotherapy after induction chemotherapy in patients with stage IIA non-small cell lung cancer (NSCLC).
  • Full results were announced in October 1998 at the American Society of Therapeutic Radiology and Oncology.
  • In March 1997 the Decision Network of the NCI voted to sponsor additional clinical indications including adult and pediatric brain tumors, as well as cancers involving the lung, head & neck, pancreas and prostrate.
  • Two phase I trials of Gd-Tex for the treatment of primary brain tumors commenced in August 1998 under a CRADA with the NCI [237538], [295592], [348919].
  • Pharmacyclics is collaborating with the NCI under a CRADA in phase I trials in primary brain tumors and pancreatic tumors [323929], [323952], [346596].
  • [MeSH-major] Drugs, Investigational / therapeutic use. Neoplasms / therapy. Organometallic Compounds / therapeutic use. Radiation-Sensitizing Agents / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11249709.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational; 0 / Gd-Tex complex; 0 / Organometallic Compounds; 0 / Radiation-Sensitizing Agents
  • [Number-of-references] 33
  •  go-up   go-down


33. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC): Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol; 2010 Apr 1;28(10):1645-51
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
  • PURPOSE: Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil.
  • The Gruppo Italiano Pancreas 1 randomized phase III trial aimed to compare gemcitabine plus cisplatin versus gemcitabine alone (ClinicalTrials.gov ID NCT00813696).
  • PATIENTS AND METHODS: Patients with locally advanced or metastatic pancreatic cancer, age 18 to 75 years, and Karnofsky performance status (KPS) > or = 50, were randomly assigned to receive gemcitabine (arm A) or gemcitabine plus cisplatin (arm B).
  • Median age was 63, 59% were male, 84% had stage IV, and 83% had KPS > or = 80.
  • Combination therapy produced more hematologic toxicity, without relevant differences in nonhematologic toxicity.
  • CONCLUSION: The addition of weekly cisplatin to gemcitabine failed to demonstrate any improvement as first-line treatment of advanced pancreatic cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00813696
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Wu J, Shao Y, Rong W, Shan Y, Gao J, Wu T: [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):497-500
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas].
  • OBJECTIVE: To improve the diagnosis and treatment of carcinoma of head of pancreas.
  • METHODS: A retrospective study was carried out to evaluate 178 patients suffering from carcinoma of head of pancreas.
  • RESULTS: Pain in the epigastrium and obstructive jaundice were observed in 70% and 74.2% of these 178 patients, both of which were of significance (P < 0.001) between stage I, II and stage III, IV disease.
  • Only 18% of patients had pain in the back, 81.3% of whom belonged to the stage IV category.
  • The detection rate of the tumor by B-ultrasound, CT and MRI were 74.2%, 87.3% and 85.5%, respectively.
  • The median survival time was 7 months in patients with unresectable tumor who received radiotherapy and/or chemotherapy.
  • By now, pancreaticoduodenectomy is still the only effective treatment for the carcinoma of head of pancreas and internal drainage is an important palliative measure.
  • [MeSH-major] Pain / etiology. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperglycemia / etiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485509.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Malayeri R, Ghassemboland M, Ranjpoor F, Maadi A: Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma. Hematol Oncol Stem Cell Ther; 2008 Oct-Dec;1(4):221-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma.
  • BACKGROUND AND OBJECTIVE: The response rate and median survival with gemcitabine monotherapy, although considered the standard treatment for inoperable and metastatic pancreatic cancer, is relatively poor.
  • We tested the efficacy and toxicity of a chemotherapy protocol consisting of gemcitabine, 5-fluorouracil (5-FU) and leucovorin in patients with inoperable or metastatic pancreatic cancer, which was shown to improve median survival in a small phase II trial.
  • PATIENTS AND METHODS: Patients older than 18 years of age with histologically or cytologically confirmed adenocarcinoma of the pancreas and bidimensionally measurable disease, and who were chemotherapy- and radiotherapy-naïve, were treated with a chemotherapy protocol consisting of gemcitabine 1250 mg/m2 on day 1, 5-FU 450 mg/m2 and leucovorin 100 mg/m2 on days 1-3.
  • The treatment was repeated every 2 weeks.
  • RESULTS: In an-intention-to-treat analysis, of 37 patients with pancreatic cancer (27 males, 10 females) (67.6% stage IVb) there were 7 (18.9%) objective partial responses (95% confidence interval, 8.33% to 29), 14 (37.8%) patients had stable disease and 16 (43.2%) had progressive disease.
  • The median response time was 3 months (range, 1.5 to 7.0 months).
  • Median overall survival time was 6.5 months (range, 1.0 to 15.5 months).
  • The response to chemotherapy was not different between males and females (P = .971).
  • No grade III/IV toxicities were seen.
  • CONCLUSION: Despite our poor survival data, the combination of gemcitabine with 5-/FU and leucovorin is an active and well-tolerated regimen in patients with pancreatic cancer that merits further evaluation in prospective randomized studies.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058477.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA: Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol; 2007 May 1;25(13):1665-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
  • PURPOSE: To test the hypothesis that dual biochemical modulation of fluorouracil (FU) in combination with mitomycin improves the survival of patients with pancreas cancer.
  • PATIENTS AND METHODS: Eligibility included stage II or III unresectable adenocarcinoma of the pancreas, performance status of 0 to 2, and adequate organ function.
  • Treatment included FU 200 mg/m2/d via continuous intravenous infusion for 4 weeks followed by 1 week of rest; leucovorin 30 mg/m2 administered via intravenous bolus infusion on days 1, 8, 15, and 22, followed by 1 week rest; mitomycin 10 mg/m2 intravenous bolus infusion every 6 weeks for a total of four doses.
  • Dipyridamole 75 mg was administered orally three times daily during the FU administration.
  • RESULTS: Fifty patients (median age, 61 years; 23 males, 27 females) with localized unresectable pancreatic cancer were eligible for this trial.
  • The most common toxicity to treatment was stomatitis.
  • There were no treatment-related deaths.
  • CONCLUSION: Potential improvement in survival and resectability of localized unresectable pancreatic cancer may be attained without radiation.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Oct 20;25(30):4861 [17947742.001]
  • (PMID = 17470859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58348; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA76429
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 64ALC7F90C / Dipyridamole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM: Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest; 2004;22(4):505-14
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
  • PURPOSE: To assess the efficacy and toxicity of combination therapy with gemcitabine and docetaxel in patients with unresectable pancreatic carcinoma.
  • PATIENTS AND METHODS: Thirty-four patients with unresectable stage III, IVA, and IVB pancreatic carcinoma were eligible for this study.
  • Due to a high incidence of myelosuppression in this first group, the treatment schedule was modified in the remaining patients to gemcitabine 1,000 mg/m2 i.v. and docetaxel 40 mg/m2 i.v. on days 1 and 8 of a 21-day schedule.
  • Partial responses noted in the pancreas and a variety of metastatic sites were maintained for 4 to 12 months (median 6 months).
  • The median time to progression was 6 months, and median survival was 10.5 months.
  • CONCLUSION: The response and survival data reported here for combination therapy with gemcitabine and docetaxel are encouraging given the poor prognosis associated with unresectable pancreatic cancer.
  • These data suggest that gemcitabine plus docetaxel may be more effective than either agent alone in the treatment of pancreatic cancer and warrants further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Neutropenia / chemically induced. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565807.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


38. Mambrini A, Sanguinetti F, Pacetti P, Caudana R, Iacono C, Guglielmi A, Guadagni S, Del Freo A, Fiorentini G, Cantore M: Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. In Vivo; 2006 Nov-Dec;20(6A):751-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience.
  • The final results of a new regimen given intra-arterially for unresectable pancreatic cancer (UPC) are presented.
  • No complications related to the angiographic procedure took place, but three tunica intima dissections of the iliac artery occurred; 7.6% of patients with partial responses and 50.7% with stable disease were observed.
  • Two hundred and one patients have died; median overall survival was 9.2 months: 10.5 and 6.6 for stage III and IV, respectively.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Celiac Artery. Chemotherapy, Cancer, Regional Perfusion. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Infusions, Intra-Arterial. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Staging. Pain / drug therapy. Pain / physiopathology. Pancreas / pathology. Pancreas / surgery. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203761.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEC protocol
  •  go-up   go-down


39. Oman M, Blind PJ, Naredi P, Gustavsson B, Hafström LO: Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. Eur J Surg Oncol; 2001 Aug;27(5):477-81
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV.
  • AIM: To explore the feasibility of intraperitoneal (IP) 5-fluorouracil (5-FU) and (IV) leucovorin for patients with advanced pancreatic carcinoma.
  • MATERIALS AND METHOD: Thirty patients (11 men), median age 65 (range 36-74 years), with a non-resectable pancreatic carcinoma in stage III (n=2) and IV (n=28) were treated with IP 5-FU 750-1000 mg/m(2)and leucovorin IV 100 mg/m(2)for 2 days every 3rd week.
  • Tumour effect was analysed with repeated computed tomography (CT) scans, performance status was estimated with Karnofsky's index (KI) and morphine consumption, and toxicity assessed using World Health Organization (WHO) criteria.
  • RESULTS: Median survival time was 7 months (range 0-21).
  • Regional and systemic toxicity: The treatment was well tolerated, with no grade III or IV complications or side-effects.
  • The median KI showed a minor reduction during treatment.
  • CONCLUSION: Intraperitoneal administration of 5-FU is feasible for patients with nonresectable pancreatic carcinoma.
  • The treatment can induce a temporary stabilization of tumour growth and eventually prolong survival without adverse effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antimetabolites, Antineoplastic / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Leucovorin / administration & dosage. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11504519.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, Tepper JE: Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer; 2006 Aug 7;95(3):260-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
  • The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined.
  • Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m(-2)) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5(1/2) weeks).
  • Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment.
  • Characteristics: median age 61 years (range 35-79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive.
  • Grade III/IV gastrointestinal or haematologic toxicities were infrequent.
  • The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):55-60 [10550827.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3218-23 [8205542.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):785-91 [10837965.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3384-9 [11013279.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):792-9 [11157033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22 [11483344.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2246-53 [11489798.001]
  • [Cites] Int J Pancreatol. 2001;29(1):9-18 [11560155.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3263-8 [11595723.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):974-81 [11704320.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4202-8 [11709563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1305-10 [12654442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):974-80 [12829132.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1461-7 [15275733.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):107-16 [15361643.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52 [15380578.001]
  • [Cites] Invest New Drugs. 1994;12(1):29-34 [7960602.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):68-71 [7481848.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):101-5 [8554969.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):867-72 [8598364.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 10):65-71 [8893885.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Radiat Oncol Investig. 1997;5(2):62-71 [9303059.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):777-82 [9815749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1125-35 [10421547.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2208-12 [10561277.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3675-80 [2340517.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):258-62 [1998982.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):52-6 [8318420.001]
  • [CommentIn] Nat Clin Pract Oncol. 2007 Mar;4(3):148-9 [17245345.001]
  • (PMID = 16868545.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA081851; United States / NCI NIH HHS / CA / 1 U10 CA81851
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2360633
  •  go-up   go-down


41. Mimatsu K, Oida T, Kuboi Y, Kawasaki A, Kanou H, Kaneda H, Amano S: A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy. Int J Clin Oncol; 2004 Jun;9(3):193-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy.
  • Conventional gastrojejunostomy has been employed for unresectable advanced gastric cancer with pyloric stenosis; however, it is often not fully effective.
  • We report a patient with unresectable gastric cancer who was effectively treated with an anticancer drug, S-1, after receiving an improved gastrojejunostomy.
  • Upper gastrointestinal endoscopy showed a Borrmann III tumor in the antrum of the stomach, and gastric roentgenography showed pyloric stenosis.
  • Preoperative findings were T3N2H0P0, stage III b.
  • At operation, the tumor was found to have invaded the duodenum and the head of the pancreas, and disseminated nodules were found in the mesenterium of the small intestine, the left diaphragm, and the round ligament of the liver.
  • A curative operation was impossible for the advanced gastric cancer.
  • She started treatment with 80 mg/day of S-1, given orally, for 28 days, followed by 14 days' rest, as 1 course.
  • During 16 courses of the treatment, she maintained a performance status of 0 to 1 and maintained quality of life.
  • This case suggested that the improved gastrojejunostomy was a useful method for treating unresectable gastric cancer, allowing the possibility of oral intake, and the use of S-1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Anastomosis, Surgical. Drug Combinations. Female. Humans. Jejunum / surgery. Middle Aged. Palliative Care. Stomach / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15221605.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down






Advertisement